Unicycive TherapeuticsUNCY
Market Cap: $40.9M
About: Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.
Employees: 14
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
6.09% more ownership
Funds ownership: 61.14% [Q1] → 67.24% (+6.09%) [Q2]
4% more funds holding
Funds holding: 23 [Q1] → 24 (+1) [Q2]
60% less capital invested
Capital invested by funds: $31.6M [Q1] → $12.7M (-$18.9M) [Q2]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Benchmark Bruce Jackson 33% 1-year accuracy 15 / 45 met price target | 592%upside $3 | Speculative Buy Reiterated | 6 Sept 2024 |
HC Wainwright & Co. Ed Arce 47% 1-year accuracy 55 / 116 met price target | 477%upside $2.50 | Buy Reiterated | 3 Sept 2024 |
HC Wainwright & Co. Ed Arce 47% 1-year accuracy 55 / 116 met price target | 477%upside $2.50 | Buy Maintained | 15 Aug 2024 |
HC Wainwright & Co. Ed Arce 47% 1-year accuracy 55 / 116 met price target | 939%upside $4.50 | Buy Reiterated | 10 Jul 2024 |
HC Wainwright & Co. Ed Arce 47% 1-year accuracy 55 / 116 met price target | 939%upside $4.50 | Buy Reiterated | 25 Jun 2024 |
Financial journalist opinion
Based on 4 articles about UNCY published over the past 30 days